GSK’s Andrew Witty knighted
pharmafile | January 3, 2012 | News story | Sales and Marketing | Andrew Witty, GSK
GlaxoSmithKline chief executive Andrew Witty and former ABPI director general Richard Barker were among the recipients in the 2012 New Year Honours List.
Witty was knighted for services to the economy and to the UK pharma industry, while Barker – who stepped down from his post in June – received an OBE for his work in the pharma sphere.
Elsewhere, there were knighthoods for John Buchanan, chairman of medical devices company Smith & Nephew, for services to industry.
In keeping with the government’s insistence that this year’s Honours were also about ‘local heroes’, there were gongs for people working in less high profile parts of the healthcare sector.
Christine Mills, founder of the cancer charity Hope for Tomorrow, whose fundraising efforts led to the UK’s first mobile chemotherapy unit, received an MBE – as did Terence Monaghan, who set up Stock Cares, a transport service that takes vulnerable residents in Essex to essential health appointments.
Six GPs also got awards, including OBEs for William Cunningham of Corbridge Health Centre in Northumberland and James Kingsland, president of the National Association of Primary Care.
Academics in health and medicine were well-represented in the list: Professor Stephen Bloom, head of diabetes and endocrinology at Imperial College London was knighted for services to medical science.
And Professors John Sissons of the University of Cambridge and Mark Pepys of University College London Medical School received knighthoods for services to research and education in clinical medicine, and to biomedicine, respectively.
There was also an OBE for Gideon Ben-Tovim, chair of Liverpool NHS Primary Care Trust, for services to health.
Adam Hill
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
